Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2000 1
2003 1
2005 1
2006 3
2007 2
2008 5
2009 4
2010 6
2011 6
2012 16
2013 5
2014 9
2015 15
2016 20
2017 19
2018 29
2019 28
2020 31
2021 34
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

216 results
Results by year
Filters applied: . Clear all
Page 1
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Leweke FM, et al. Transl Psychiatry. 2012 Mar 20;2(3):e94. doi: 10.1038/tp.2012.15. Transl Psychiatry. 2012. PMID: 22832859 Free PMC article. Clinical Trial.
In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. ...The results suggest that inhibition of …
In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsy …
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. McGuire P, et al. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. Am J Psychiatry. 2018. PMID: 29241357 Clinical Trial.
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. ...CONCLUSIONS: These findings suggest that CBD has beneficial effe …
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed th …
Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies.
Schoevers J, Leweke JE, Leweke FM. Schoevers J, et al. Curr Opin Psychiatry. 2020 May;33(3):185-191. doi: 10.1097/YCO.0000000000000596. Curr Opin Psychiatry. 2020. PMID: 32073423 Review.
PURPOSE OF REVIEW: The most recent studies published or initiated in the last 18 months, investigating cannabidiol in the treatment of symptoms of schizophrenia and related conditions are summarized, including observed tolerability and reported side-effects. ...SUMM …
PURPOSE OF REVIEW: The most recent studies published or initiated in the last 18 months, investigating cannabidiol in the treatment o …
The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis.
Kopelli E, Samara M, Siargkas A, Goulas A, Papazisis G, Chourdakis M. Kopelli E, et al. Psychiatry Res. 2020 Sep;291:113246. doi: 10.1016/j.psychres.2020.113246. Epub 2020 Jun 22. Psychiatry Res. 2020. PMID: 32599446
The purpose of the present meta-analysis was to assess the efficacy of cannabidiol (CBD) oil in patients with schizophrenia. A search was conducted in EMBASE, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and WHO International …
The purpose of the present meta-analysis was to assess the efficacy of cannabidiol (CBD) oil in patients with schizophrenia. A …
Cannabidiol in Anxiety and Sleep: A Large Case Series.
Shannon S, Lewis N, Lee H, Hughes S. Shannon S, et al. Perm J. 2019;23:18-041. doi: 10.7812/TPP/18-041. Perm J. 2019. PMID: 30624194 Free PMC article.
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. ...In this chart review, CBD was well tolerated in all but 3 patients. CONCLUSION: Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed.. …
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. ...In this chart review, CBD was well tolerated in …
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. García-Gutiérrez MS, et al. Biomolecules. 2020 Nov 19;10(11):1575. doi: 10.3390/biom10111575. Biomolecules. 2020. PMID: 33228239 Free PMC article. Review.
Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. ...
Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displa …
Improving Current Treatments for Schizophrenia.
Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Maric NP, et al. Drug Dev Res. 2016 Nov;77(7):357-367. doi: 10.1002/ddr.21337. Epub 2016 Sep 16. Drug Dev Res. 2016. PMID: 27633376 Review.
The first relatively specific treatment of schizophrenia started about 60 years ago with the antipsychotic chlorpromazine. ...In addition, we emphasize that the development of the novel compounds to target the underlying cognitive dysfunction and negative symptom dimension …
The first relatively specific treatment of schizophrenia started about 60 years ago with the antipsychotic chlorpromazine. ...In addi …
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. Boggs DL, et al. Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5. Psychopharmacology (Berl). 2018. PMID: 29619533 Clinical Trial.
RATIONALE: Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS). ...CONCLUSIONS: A …
RATIONALE: Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; how …
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experiment …
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subj …
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
Loss CM, Teodoro L, Rodrigues GD, Moreira LR, Peres FF, Zuardi AW, Crippa JA, Hallak JEC, Abílio VC. Loss CM, et al. Front Pharmacol. 2021 Feb 4;11:635763. doi: 10.3389/fphar.2020.635763. eCollection 2020. Front Pharmacol. 2021. PMID: 33613289 Free PMC article. Review.
Schizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental disorders that cause high levels of functional disabilities. ...In summary, the results point to CBD's beneficial potential for the progression of these disorders supporting further
Schizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental disorders that cause high levels of functional d
216 results